<DOC>
	<DOCNO>NCT02120352</DOCNO>
	<brief_summary>This study Phase IIb , randomize , multicentre , parallel group , open-label , study overall objective evaluate antiviral activity , tolerability , safety two intramuscular ( IM ) dose regimen GSK744 LA plus TMC278 LA , relative GSK744 30 milligram ( mg ) plus Abacavir/Lamivudine ( ABC/3TC ) give orally daily ( QD ) , HIV-1 infect antiretroviral-na√Øve subject . GSK744 oral formulation GSK1265744 , GSK744 LA long act injectable formulation GSK1265744 TMC278 LA long act injectable formulation TMC278 . The study consist three part : Induction Period , Maintenance Period Extension Period . There also Long-Term Follow Up Period subject withdraw study receive least one dose GSK744 LA / TMC278 LA . In Induction Period , eligible subject receive combination oral regimen 30 mg GSK744 600/300 mg ABC/3TC , daily 20 week . In Maintenance Period , eligible subject randomize 2:2:1 Day 1 receive IM regimen GSK744 LA 400 mg + TMC278 LA 600 mg every 4 week 96 week ( Q4W ) , IM regimen GSK744 LA 600 mg + TMC278 LA 900 mg every 8 week 96 week ( Q8W ) , continue oral Induction Period regimen GSK744 30 mg + ABC/3TC daily 96 week ( 104 week continue Extension Period ) . The Extension Period allow collection long term efficacy safety tolerability data subject receive GSK744 LA TMC278 LA . The study involve sufficient subject screen order ensure total approximately 265 subject begin Induction Period approximately 225 subject randomized Maintenance Period .</brief_summary>
	<brief_title>A Phase IIb Study Evaluate Long-Acting Intramuscular Regimen Maintenance Virologic Suppression ( Following Induction With Oral Regimen GSK1265744 Abacavir/Lamivudine ) Human Immunodeficiency Virus Type 1 ( HIV-1 ) Infected , Antiretroviral Therapy-Naive Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Subjects screen study must HIV1 infect &gt; =18 year age . A female subject eligible enter participate study : nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea &gt; =45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy ; childbearing potential negative pregnancy test Screening first day Induction Period agree use one follow method contraception avoid pregnancy 2 week prior administration IP , throughout study , least 2 week discontinuation oral study medication least 52 week discontinuation GSK744 LA TMC278 LA : Complete abstinence intercourse ( subject 's prefer usual lifestyle ) ; double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; approve hormonal contraception ; intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ; male partner sterilization prior female subject 's entry study , male sole partner subject ; method publish data show low expected failure rate &lt; 1 % per year ; contraception method must use consistently accordance approved product label . All subject participate study must follow safe sexual practice include use effective barrier method ( e.g . male condom/spermicide ) minimize risk HIV transmission . HIV1 infection document Screening plasma HIV1 RNA &gt; =1000 c/mL . CD4+ cell count &gt; =200 cells/mm^3 ( high local guideline dictate ) . ARTnaive define 10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection . Any previous exposure HIV integrase inhibitor nonnucleoside reverse transcriptase inhibitor exclusionary . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Women breastfeed . Any evidence screen active Center Disease Prevention Control ( CDC ) Category C disease , except cutaneous Kaposi 's sarcoma require systemic therapy . Subjects know moderate severe hepatic impairment . Any preexist physical mental condition ( include substance abuse disorder ) , opinion Investigator , may interfere subject 's ability comply dose schedule and/or protocol evaluation may compromise safety subject . Subject , investigator 's judgment , pose significant suicide risk . Recent history suicidal behavior and/or suicidal ideation may consider evidence serious suicide risk . The subject tattoo dermatological condition overlie gluteus region may interfere interpretation injection site reaction . History ongoing clinically relevant hepatitis within previous 6 month , include chronic Hepatitis B virus ( HBV ) infection ( HBsAg positive ) . Asymptomatic individual chronic hepatitis C virus ( HCV ) infection exclude , however Investigators must carefully assess therapy specific HCV infection require ; subject anticipate require therapy randomize portion study must exclude . History liver cirrhosis without hepatitis viral coinfection . Ongoing clinically relevant pancreatitis . History follow cardiac disease : myocardial infarction , congestive heart failure , document hypertrophic cardiomyopathy , sustain ventricular tachycardia . Personal known family history prolong QT syndrome . Any condition , opinion Investigator , may interfere absorption , distribution , metabolism excretion drug render subject unable receive study medication . History presence allergy intolerance study drug component drug class . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia must enrol . Current anticipate need chronic anticoagulation . Any evidence primary resistance base presence major resistanceassociated mutation Screening result , know , historical resistance test result . Any verified Grade 4 laboratory abnormality . Any acute laboratory abnormality Screening , , opinion Investigator , would preclude subject 's participation study investigational compound . Subject estimate creatinine clearance &lt; 50 mL/min via CockcroftGault method . Alanine aminotransferase ( ALT ) &gt; =5 time Upper limit normal ( ULN ) . Subjects ALT &gt; 2xULN &lt; 5xULN may participate study , opinion Investigator GlaxoSmithKline ( GSK ) medical monitor lab abnormality interfere study procedure compromise subject safety . Alanine aminotransferase ( ALT ) &gt; =3xULN bilirubin &gt; =1.5xULN ( &gt; 35 % direct bilirubin ) . Any clinically significant find screen Baseline electrocardiograph ( ECG ) , specifically : Heart rate &lt; 45 &gt; 100 beat per minute ( bpm ) ( Males ) &lt; 50 &gt; 100 bpm ( Females ) ( 100 110 bpm rechecked within 30 minute verify eligibility ) , QRS duration &gt; 120 millisecond ( msec ) , QTc interval ( B F ) &gt; 450 msec ; nonsustained ( &gt; =3 consecutive beat ) sustain ventricular tachycardia ; sinus pause &gt; 2.5 second ; 2nd degree ( Type II ) high atrioventricular ( AV ) block ; evidence WPW ( Wolff ParkinsonWhite ) syndrome ( ventricular preexcitation ) ; pathologic Q wave define Q wave &gt; 40msec OR depth &gt; 0.4 mV ; significant arrhythmia ( either ECG history ) , opinion Investigator GSK medical monitor , interfere safety individual subject . Subjects human leukocyte antigen ( HLA ) B*5701 positive unable use alternative nucleoside reverse transcriptase inhibitor ( NRTI ) backbone ( subject HLAB*5701 positive may enrol use alternative NRTI backbone contain abacavir ) . Exposure experimental drug and/or experimental vaccine within 28 day 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose IP . Treatment follow agent within 28 day Screening ; radiation therapy , cytotoxic chemotherapeutic agent , tuberculosis therapy Immunomodulators alter immune response ( systemic corticosteroid , interleukin , interferon ) Treatment HIV1 immunotherapeutic vaccine within 90 day Screening . Treatment agent , except recognize ART allow , documented activity HIV1 within 28 day first dose IP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>bi-monthly</keyword>
	<keyword>GSK744</keyword>
	<keyword>injectable</keyword>
	<keyword>long act</keyword>
	<keyword>maintenance</keyword>
	<keyword>abacavir</keyword>
	<keyword>every month</keyword>
	<keyword>rilpivirine</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>TMC278 LA</keyword>
	<keyword>RPV</keyword>
	<keyword>non-nucleoside reverse transcriptase inhibitor</keyword>
	<keyword>LA</keyword>
	<keyword>monthly</keyword>
	<keyword>GSK1265744</keyword>
	<keyword>induction</keyword>
	<keyword>treatment satisfication</keyword>
	<keyword>daily</keyword>
	<keyword>lamivudine</keyword>
	<keyword>adherence</keyword>
	<keyword>TMC278</keyword>
	<keyword>therapy-naive</keyword>
</DOC>